Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers

Journal of Obstetrics and Gynaecology

Volumn 31, Issue 6, 2011, Pages 465-472

  Walfisch, A ^a   Al Maawali, A ^a   Moretti, M E ^a   Nickel, C ^a   Koren, G ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

1st trimester; ACE inhibitors; Angiotensin receptor blockers; Teratogenicity

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

BODY MASS; CONGENITAL MALFORMATION; DRUG EXPOSURE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MATERNAL AGE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RISK ASSESSMENT;

EID: 80051512865     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.3109/01443615.2011.579197     Document Type: Review

References (41)

1. Bar J, Hod M, Merlob P. 1997. Angiotensin converting enzyme inhibitors use in the first trimester of pregnancy. International Journal of Risk and Safety in Medicine 10:23-26. (Pubitemid 27321609)
2. Berkane N, Carlier P, Verstraete L, Mathieu E, Heim N, Uzan S. 2004. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Research Part A: Clinical and Molecular Teratology 70:547-549. (Pubitemid 39167071)
3. Biswas PN, Wilton LV, Shakir S W. 2002. Te safety of valsartan: results of a postmarketing surveillance study on 12,881 patients in England. Journal of Human Hypertension 16:795-803. (Pubitemid 36007933)
4. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. 1999. Traditional reviews, meta-analyses and pooled analyses in epidemiology. International Journal of Epidemiology 28:1-9. (Pubitemid 29086203)
5. Boix E, Zapater P, Pico A, Moreno O. 2005. Teratogenicity with angiotensin II receptor antagonists in pregnancy. Journal of Endocrinological Investigation 28:1029-1031. (Pubitemid 43265771)
6. Bos-Tompson MA, Hillaire-Buys D, Muller F, Dechaud H, Mazurier E, Boulot P et al. 2005. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up af er birth. Annals of Pharmacotherapy 39: 157-161. (Pubitemid 40052394)
7. Briggs GG, Nageotte MP. 2001. Fatal fetal outcome with the combined use of valsartan and atenolol. Annals of Pharmacotherapy 35:859-861. (Pubitemid 32678707)
8. Briggs GG, Freeman RK, Yaffe SJ. 2008. Drugs in pregnancy and lactation. 8th ed. Baltimore: Lippincott Williams and Wilkins. p. 614, 1058.
9. Burrows RF, Burrows EA. 1998. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology 38:306.
10. Chung NA, Lip GY, Beevers M, Beevers DG. 2001. Outcomes in women given valsartan early in pregnancy [letter]. Lancet 357:1620.
11. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS et al. 2006. Major congenital malformations af er first-trimester exposure to ACE inhibitors. New England Journal of Medicine 354:2443-2451. (Pubitemid 43855047)
12. Correa-Villaseñor A, Cragan J, Kucik J, O'Leary L, Siffel C, Williams L. 2003. Te Metropolitan Atlanta Congenital Defects Program: 35 years of birth defects surveillance at the Centers for Disease Control and Prevention. Birth Defects Research Part A: Clinical and Molecular Teratology 67:617-624. (Pubitemid 37222110)
13. Cournot MP, Vial T, Carlier P, Jonville-Bera AP, Alt M, ElefanTe et al. 2006. Angiotensin-converting enzyme (ACE) inhibitors during first trimester of pregnancy: A French prospective collaborative study. Drug Safety 29:911-1010.
14. Diav-Citrin O, Shechtman S, Halberstadt Y, Finkel-Pekarsky V, Wajnberg R, Arnon J et al. 2011. Pregnancy outcome af er in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reproductive Toxicology [Epub ahead of print].
15. Dickersin K, Min YI. 1993. NIH clinical trials and publication bias. Online Journal of Current Clinical Trials April:50.
16. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. 1991. Publication bias in clinical research. Lancet 337:867-872.
17. Gersak K, Cvijic M, Kornhauser CL. 2009. Angiotensin II receptor blockers in pregnancy: A report of five cases. Reproductive Toxicology 28:109-112.
18. Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE, Geiss L et al. 2004. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care 27:2806-2812. (Pubitemid 39565041)
19. Higgins JP, Tompson SG, Deeks JJ, Altman DG. 2003. Measuring inconsistency in meta-analyses. British Medical Journal 327:557-560. (Pubitemid 37088507)
20. Hippisley-Cox J, Pringle M. 2004. Prevalence, care, and outcomes for patients with diet-controlled diabetes in general practice: cross sectional survey. Lancet 364:423-428. (Pubitemid 39036889)
21. Kallen BA, Otterblad OP. 2003. Maternal drug use in early pregnancy and infant cardiovascular defect. Reproductive Toxicology 17:255-261. (Pubitemid 36626946)
22. Kalyoncu NI, Yaris F, Kadioglu M, Kesim M, Ulku C, Yaris E et al. 2005. Pregnancy outcome following exposure to orlistat, ramipril, glimepiride in a woman with metabolic syndrome. Saudi Medical Journal 26:497-499. (Pubitemid 40590313)
23. Karthikeyan VJ, Ferner RE, Baghdadi S, Lane DA, Lip GY, Beevers DG. 2011. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: A report of ninetyone pregnancies. Journal of Hypertension 29:396-399.
24. Kref-Jais C, Plouin PF, Tchobroutsky C, Boutroy MJ. 1988. Angiotensin-converting enzyme inhibitors in pregnancy: A survey of 22 patients given captopril and nine given enalapril. British Journal of Obstetrics and Gynaecology 95:420-422.
25. Lain KY, Roberts JM. 2002. Contemporary concepts of the pathogenesis and management of preeclampsia. Journal of the American Medical Association 287:3183-3186. (Pubitemid 34686089)
26. Lennestäl R, OtterbladOlausson P, Kallen B. 2009. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. European Journal of Clinical Pharmacology 65:615-625.
27. Lip GY, Churchill D, Beevers M, Auckett A, Beevers DG. 1997. Angiotensin-converting-enzyme inhibitors in early pregnancy. Lancet 350:1446-1447. (Pubitemid 28036870)
28. Malm H, Artama M, Gissler M, Klaukka T, Merilainen J, Nylander O et al. 2008. First trimester use of ACE-inhibitors and risk of major malformations. Reproductive Toxicology 26:67.
29. Mann RD, Mackay F, Pearce G, Freemantle S, Wilton LV. 1999. Losartan: A study of pharmacovigilance data on 14 522 patients. Journal of Human Hypertension 13:551-557. (Pubitemid 29386845)
30. McElhatton PR, Stephens S, Wilson G, Tomas SH. 2008. Preliminary data on exposure to angiotensin-converting enzyme inhibitors (ACEI) during pregnancy. Reproductive Toxicology 26:67.
31. CDC (Centers for Disease Control and Prevention). 1997. Post-marketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy United States, Canada, and Israel. 1987-1995. Journal of the American Medical Association 277:1193-1194 and Morbidity and Mortality Weekly Report 46:240-242.
32. Nayar B, Singhal A, Aggarwal R, Malhotra N. 2003. Losartan induced fetal toxicity. Indian Journal of Pediatrics 70:923-924. (Pubitemid 38017033)
33. Piper JM, Ray WA, Rosa FW 1992. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstetrics and Gynecology 80:429-432.
34. Ray JG, Vermeulen MJ, Koren G. 2007. Taking ACE inhibitors during early pregnancy: is it safe? Canadian Family Physician 53:1439-1440. (Pubitemid 351194553)
35. Rosenthal R. 1979. Te file drawer problem and tolerance for null results. Psychological Bulletin 86:638-641.
36. Schaefer C. 2003. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Research Part A: Clinical and Molecular Teratology 67:591-594. (Pubitemid 37247675)
37. Serreau R, Luton D, Macher MA, Delezoide AL, Garel C, Jacqz-Aigraina E. 2005. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. British Journal of Obstetrics and Gynaecology 112:710-712. (Pubitemid 40852836)
38. Stefensen FH, Nielsen GL, Sorensen HT, Olesen C, Olsen J. 1998. Pregnancy outcome with ACE-inhibitor use in early pregnancy [letter]. Lancet 351: 96.
39. Tabacova S, Little R, Tsong Y, Vega A, Kimme AC. 2003. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiology and Drug Safety 12:633-646. (Pubitemid 38028777)
40. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos MP et al. 2010. Te Newcastle - Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Ottawa Hospital Research Institute. Ottawa, Canada. Available at: www.ohri.ca/programs/clinical- epidemiology/oxford.htm
41. Yip SK, Leung TN, Fung HY 1998. Exposure to angiotensin-converting enzyme inhibitors during first trimester: Is it safe to fetus? Acta Obstetricia et Gynecologica Scandinavica 77:570-571. (Pubitemid 28263831)